Cogent Biosciences Inc

NASDAQ COGT

Data sourced from

and

Download Data

Cogent Biosciences Inc Pre-Tax Margin for the quarter ending March 31, 2024

Cogent Biosciences Inc Pre-Tax Margin is NA for the quarter ending March 31, 2024. Pre-tax margin represents the proportion of a company's earnings before taxes (EBT) to its revenue. It is calculated by dividing the EBT by the revenue. This ratio indicates the profitability of the company's operations before the impact of taxes. A higher pre-tax margin suggests that the company generates a larger proportion of revenue as pre-tax profit, indicating stronger operational performance and efficiency.

Cogent Biosciences Inc Pre-Tax Margin for the quarter ending March 31, 2020 was -87.34%, a 77.48% change year over year.

NASDAQ: COGT

Cogent Biosciences Inc

CEO	Mr. Andrew R. Robbins M.B.A.
IPO Date	March 29, 2018
Location	United States
Headquarters	200 Cambridge Park Drive, Cambridge, MA, United States, 02140
Employees	164
Sector	Healthcare
Industry	Biotechnology

Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Key trends